TriCAR T-cells

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTriCAR T-cells
Drug Alias NameTriCAR T-cells (Children’s Hospital of Los Angeles/Baylor College of Medicine/Texas Children's Hospital/Beckman Research Institute/University of Southern California/University of Houston/Charite Universitaetsmedizin Berlin)triple anti-CD19/anti-CD20/anti-CD22 CAR T-cell therapy (Children’s Hospital of Los Angeles/Baylor College of Medicine/Texas Children's Hospital/Beckman Research Institute/University of Southern California/University of Houston/Charite Universitaetsmedizin Berlin)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsCD22 modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD20B-lymphocyte antigen CD19CD22
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChildren'S Hospital Los Angeles
China Registration ClassN/A

Develop Information

Active CompaniesBeckman Research InstituteChildren'S Hospital Los AngelesUniversity Of Southern California +[7] 
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A